InvestorsHub Logo

TheHound

09/25/17 8:18 AM

#198027 RE: Phoenix300 #198011

http://www.ipharminc.com/press-release/2017/8/6/innovation-pharmaceuticals-completes-patient-enrollment-in-phase-2-study-of-brilacidin-for-the-prevention-of-severe-oral-mucositis

;-) looking good Mata!


Matagordaville
Sunday, 09/24/17 10:26:17 PM

B-OM P2 Topline results release October 30, my wag.

Then they will apply for Breakthrough Designation if topline results mimic the interim results.

Getting closer.